UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2011

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware000-5076111-3146460(State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

14 Plaza Drive, Latham, New York 12110

(Address of Principal Executive Offices) (Zip Code)

(518) 798-1215

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 19, 2011, Scott J. Solano resigned his position as Senior Vice President and Chief Technology Officer of AngioDynamics, Inc. (the "<u>Company</u>") effective October 14, 2011. Mr. Solano will not receive any severance or termination payments from the Company in connection with his resignation.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release dated September 22, 2011.

SIGNATURE

	Pursuant to the requirements	of the Securities Exchange	Act of 1934,	the registrant has duly	caused this report to l	be signed on its	behalf by the
undersi	gned hereunto duly authorized.						

ANGIODYNAMICS, INC. (Registrant)

Date: September 22, 2011 By: /s/ D. Joseph Gersuk

D. Joseph Gersuk Chief Financial Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated September 22, 2011.



FOR IMMEDIATE RELEASE

Company Contact:

Angio Dynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@Angio Dynamics.com

Investor Relations Contacts:

EVC Group, Inc. Greg Gin/Doug Sherk (646) 445-4801; (415) 652-9100 ggin@evcgroup.com; dsherk@evcgroup.com

Media Contact:

EVC Group, Inc. Chris Gale (646) 201-5431 cgale@evcgroup.com

Scott Solano to Depart AngioDynamics

ALBANY, N.Y. (September 22, 2011) – AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that Scott Solano, Senior Vice President and Chief Technology Officer, has resigned his position effective October 14, 2011, to pursue other interests. Mr. Solano joined AngioDynamics in September 2010.

"We are disappointed that Scott has decided to leave AngioDynamics," said Joseph DeVivo, President & CEO. "During the past year, Scott contributed significantly to our technology direction and product pipeline. With Scott's full cooperation, we are implementing an orderly transition of his responsibilities."

"My decision to leave AngioDynamics is a personal one," said Mr. Solano. "I believe the Company is well positioned for future growth and wish all of the employees great success in the years ahead."

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.

###